Curaleaf (OTCMKTS:CURLF) Upgraded to “Strong-Buy” at Zacks Research

Zacks Research upgraded shares of Curaleaf (OTCMKTS:CURLF) from a hold rating to a strong-buy rating in a report issued on Tuesday,Zacks.com reports.

Curaleaf Stock Down 1.6%

Shares of CURLF opened at $9.75 on Tuesday. The firm has a market cap of $2.28 billion, a P/E ratio of -25.00 and a beta of 1.51. Curaleaf has a 12 month low of $2.83 and a 12 month high of $15.15. The stock’s 50 day moving average is $7.56 and its two-hundred day moving average is $7.56. The company has a current ratio of 1.56, a quick ratio of 0.74 and a debt-to-equity ratio of 1.05.

Curaleaf (OTCMKTS:CURLF) last announced its earnings results on Tuesday, May 5th. The company reported $0.27 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.24) by $0.51. Curaleaf had a negative return on equity of 8.11% and a negative net margin of 7.76%.The firm had revenue of $324.23 million for the quarter, compared to analyst estimates of $316.62 million. Analysts predict that Curaleaf will post -0.31 earnings per share for the current fiscal year.

Curaleaf Company Profile

Curaleaf Holdings, Inc is a leading American cannabis company engaged in the cultivation, processing and distribution of both medical and adult-use cannabis products. Headquartered in Wakefield, Massachusetts, Curaleaf operates cultivation facilities, processing centers and retail dispensaries across multiple U.S. jurisdictions. The company’s vertically integrated model allows it to manage the entirety of its supply chain, from seed to sale, ensuring consistent quality and compliance with stringent regulatory requirements.

Curaleaf’s product portfolio spans a wide range of formats, including premium flower, vaporizer cartridges, edibles, tinctures, topicals and concentrates.